You are here: Industry Insights > therapy

News List

Cell therapy rejected for aggressive adult lymphoma on the NHS europeanpharmaceuticalreview
April 18, 2019
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS…
Catalent to Acquire Paragon for $1.2B contractpharma
April 16, 2019
To provide new expertise and capabilities in fast-growing gene therapy space.
Cryoport, Celularity Enter Supply Chain Partnership contractpharma
April 15, 2019
Celularity to use Cryoport’s temperature controlled logistics solutions...
Paragon Opens New Biomanufacturing Facility in MD contractpharma
April 15, 2019
New facility is equipped with several 500L and 2000L single-use bioreactors for clinical through commercial material production...
HPV Therapy INO-3106 Demonstrates Clinical Efficacy against Rare Respiratory Tract Tumors americanpharmaceuticalreview
April 11, 2019
HPV Therapy INO-3106 Demonstrates Clinical Efficacy against Rare Respiratory Tract Tumors.
Six new licensing deals for drug and gene therapy development firm europeanpharmaceuticalreview
April 10, 2019
Oxford Genetics has won six new licensing deals for its scalable drug and gene therapy manufacturing in the synthetic biology sector…
TMS Health Solutions Provides an Innovative Approach to Therapy biospectrumasia
April 03, 2019
When it comes to clinical depression, many people do not even know where to start in order to begin the process of improving their lives.
UK opens doors to cannabis-based therapies via NHS pharmaphorum
December 17, 2018
Medical cannabis is available to certain patients across the UK for the first time from today.The groundbreaking decision was made so that .....
Norgine buys rights to sell Shield’s iron deficiency therapy pharmatimes
September 20, 2018
Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.
FDA Grants Breakthrough Therapy Designation for CA-008 americanpharmaceuticalreview
September 12, 2018
Concentric Analgesics has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for CA-008 in post-surgical pain. CA-008 is a first-in-class non-opioid therapeutic that rapidly converts to capsaicin, a potent TRPV1-ago

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page